1. Home
  2. EAT vs CORT Comparison

EAT vs CORT Comparison

Compare EAT & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brinker International Inc.

EAT

Brinker International Inc.

SELL

Current Price

$193.12

Market Cap

8.1B

ML Signal

SELL

Logo Corcept Therapeutics Incorporated

CORT

Corcept Therapeutics Incorporated

SELL

Current Price

$69.04

Market Cap

9.7B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
EAT
CORT
Founded
1975
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.1B
9.7B
IPO Year
1994
2001

Fundamental Metrics

Financial Performance
Metric
EAT
CORT
Price
$193.12
$69.04
Analyst Decision
Strong Buy
Buy
Analyst Count
23
5
Target Price
★ $264.73
$142.60
AVG Volume (30 Days)
★ 1.3M
1.2M
Earning Date
10-28-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 30.65
N/A
EPS
★ 2.64
1.13
Revenue
★ $5,807,400,000.00
$761,407,000.00
Revenue This Year
$8.63
$52.09
Revenue Next Year
$2.94
$44.73
P/E Ratio
$73.26
★ $61.24
Revenue Growth
7.86
★ 12.79
52 Week Low
$123.10
$28.66
52 Week High
$254.99
$126.38

Technical Indicators

Market Signals
Indicator
EAT
CORT
Relative Strength Index (RSI) 43.78 23.49
Support Level $186.08 $30.24
Resistance Level $228.57 $122.93
Average True Range (ATR) 11.64 4.59
MACD -1.41 -0.31
Stochastic Oscillator 15.25 3.51

Price Performance

Historical Comparison
EAT
CORT

About EAT Brinker International Inc.

Brinker International is a leading casual dining operator and franchisor. Chili's, its largest banner and the second-largest casual dining concept in the US, is known for its American/Southwest-inspired menu. In fiscal 2026, the segment generated $5.3 billion in revenue (92% of consolidated sales) across 1,114 company-owned restaurants in the US and 469 franchised locations (the bulk of which are in international markets). The Italian casual-dining concept Maggiano's accounts for the remainder of the business, with 52 domestic units.

About CORT Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

Share on Social Networks: